Protein farnesyltransferase: flexible docking studies on inhibitors using computational modeling
- PMID: 16607571
- DOI: 10.1007/s10822-005-9030-2
Protein farnesyltransferase: flexible docking studies on inhibitors using computational modeling
Abstract
Using MacroModel, peptide, peptidomimetic and non-peptidomimetic inhibitors of the zinc metalloenzyme, farnesyltransferase (FTase), were docked into the enzyme binding site. Inhibitor flexibility, farnesyl pyrophosphate substrate flexibility, and partial protein flexibility were taken into account in these docking studies. In addition to CVFM and CVIM, as well as our own inhibitors FTI-276 and FTI-2148, we have docked other farnesyltransferase inhibitors (FTIs) including Zarnestra, which presently is in advanced clinical trials. The AMBER* force field was employed, augmented with parameters that were derived for zinc. A single binding site model that was derived from the crystal structure of CVFM complexed with farnesyltransferase and farnesylpyrophosphate was used for these studies. The docking results using the lowest energy structure from the simulation, or one of the lowest energy structures, were generally in excellent agreement with the X-ray structures. One of the most important findings of this study is that numerous alternative conformations for the methionine side chain can be accommodated by the enzyme suggesting that the methionine pocket can tolerate groups larger than methionine at the C-terminus of the tetrapeptide and suggesting alternative locations for the placement of side chains that may improve potency.
Similar articles
-
The crystal structure of human protein farnesyltransferase reveals the basis for inhibition by CaaX tetrapeptides and their mimetics.Proc Natl Acad Sci U S A. 2001 Nov 6;98(23):12948-53. doi: 10.1073/pnas.241407898. Epub 2001 Oct 30. Proc Natl Acad Sci U S A. 2001. PMID: 11687658 Free PMC article.
-
Structure based design of benzophenone-based non-thiol farnesyltransferase inhibitors.Curr Pharm Des. 2002;8(19):1713-22. doi: 10.2174/1381612023394061. Curr Pharm Des. 2002. PMID: 12171543 Review.
-
Cocrystal structure of protein farnesyltransferase complexed with a farnesyl diphosphate substrate.Biochemistry. 1998 Jul 7;37(27):9612-8. doi: 10.1021/bi980708e. Biochemistry. 1998. PMID: 9657673
-
Protein farnesyltransferase isoprenoid substrate discrimination is dependent on isoprene double bonds and branched methyl groups.Biochemistry. 2001 Oct 16;40(41):12254-65. doi: 10.1021/bi011133f. Biochemistry. 2001. PMID: 11591144
-
Farnesyltransferase and geranylgeranyltransferase I: structures, mechanism, inhibitors and molecular modeling.Drug Discov Today. 2015 Feb;20(2):267-76. doi: 10.1016/j.drudis.2014.10.002. Epub 2014 Oct 16. Drug Discov Today. 2015. PMID: 25450772 Review.
Cited by
-
From laptop to benchtop to bedside: structure-based drug design on protein targets.Curr Pharm Des. 2012;18(9):1217-39. doi: 10.2174/138161212799436386. Curr Pharm Des. 2012. PMID: 22316152 Free PMC article. Review.
-
Imidazole-containing farnesyltransferase inhibitors: 3D quantitative structure-activity relationships and molecular docking.J Comput Aided Mol Des. 2009 Jul;23(7):431-48. doi: 10.1007/s10822-009-9278-z. Epub 2009 May 29. J Comput Aided Mol Des. 2009. PMID: 19479325
-
Matrix metalloproteinase-1 contribution to sarcoma cell invasion.J Cell Mol Med. 2012 Jun;16(6):1331-41. doi: 10.1111/j.1582-4934.2011.01402.x. J Cell Mol Med. 2012. PMID: 21801306 Free PMC article.
-
Library Screening, In Vivo Confirmation, and Structural and Bioinformatic Analysis of Pentapeptide Sequences as Substrates for Protein Farnesyltransferase.Int J Mol Sci. 2024 May 13;25(10):5324. doi: 10.3390/ijms25105324. Int J Mol Sci. 2024. PMID: 38791363 Free PMC article.
References
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources